Trial reportFrontiers in pediatrics2026
Evaluation of umbilical cord blood presepsin in the diagnosis of neonatal early-onset sepsis.
Trial report in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to measure soluble leukocyte differentiation antigen 14 (presepsin) levels in umbilical cord blood from neonates with risk factors for early-onset sepsis (EOS). The objectives were to evaluate presepsin's diagnostic value for EOS and determine its optimal diagnostic cutoff in umbilical cord blood. Study design: In this single-center prospective study, we enrolled neonates born between June 2024 and September 2025 at our hospital who presented with EOS risk factors. Infants were stratified into two groups based on EOS development: the EOS group and the non-EOS group. Within 24 h of birth, umbilical cord blood and venous blood samples were collected for analysis. We measured presepsin levels in cord blood and evaluated complete blood counts, C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 (IL-6) in both cord and peripheral blood. These biomarkers were compared to assess presepsin's diagnostic performance relative to traditional inflammatory markers for neonatal EOS. Results: The study included 195 eligible neonates. Umbilical cord presepsin levels were significantly elevated in the EOS group compared to controls (1,084.51 pg/mL vs. 618.94 pg/mL, Conclusion: Umbilical cord presepsin showed higher diagnostic accuracy than traditional inflammatory markers for neonatal EOS. and the optimal cut-off value of umbilical-blood presepsin to predict EOS was 800.91 pg/mL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.